Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PODD 
Insulet Corporation (PODD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: PODD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
23 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $363.62
1 Year Target Price $363.62
| 14 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.99% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 21.96B USD | Price to earnings Ratio 94.82 | 1Y Target Price 363.62 |
Price to earnings Ratio 94.82 | 1Y Target Price 363.62 | ||
Volume (30-day avg) 23 | Beta 1.4 | 52 Weeks Range 230.05 - 353.50 | Updated Date 10/30/2025 |
52 Weeks Range 230.05 - 353.50 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When Before Market | Estimate 1.14 | Actual - |
Profitability
Profit Margin 10.01% | Operating Margin (TTM) 18.66% |
Management Effectiveness
Return on Assets (TTM) 7.75% | Return on Equity (TTM) 19.18% |
Valuation
Trailing PE 94.82 | Forward PE 54.95 | Enterprise Value 22255453352 | Price to Sales(TTM) 9.31 |
Enterprise Value 22255453352 | Price to Sales(TTM) 9.31 | ||
Enterprise Value to Revenue 9.43 | Enterprise Value to EBITDA 54.64 | Shares Outstanding 70392535 | Shares Floating 70082808 |
Shares Outstanding 70392535 | Shares Floating 70082808 | ||
Percent Insiders 0.28 | Percent Institutions 102.17 |
Upturn AI SWOT
Insulet Corporation
Company Overview
History and Background
Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. The company focuses on developing and commercializing innovative technologies for the management of diabetes. A significant milestone was the introduction of the Omnipod Insulin Management System, a tubeless insulin pump, which revolutionized insulin delivery.
Core Business Areas
- Insulin Delivery Systems: Designs, develops, and commercializes the Omnipod Insulin Management System, a disposable, tubeless insulin pump. Also includes the Omnipod DASH and Omnipod 5 systems.
Leadership and Structure
Jim Hollingsworth serves as the Interim Chief Executive Officer. The organizational structure includes departments such as Research and Development, Operations, Sales and Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Omnipod Insulin Management System: A tubeless insulin pump system that delivers continuous insulin without the need for injections. Key competitor is Medtronic (MDT), Tandem Diabetes Care (TNDM) and others. Market share data is provided in the 'Competitors' section.
- Omnipod DASH: A next-generation personal diabetes manager (PDM) that integrates with the Omnipod System, enabling wireless monitoring and control. Key competitor is Medtronic (MDT), Tandem Diabetes Care (TNDM) and others. Market share data is provided in the 'Competitors' section.
- Omnipod 5: An advanced closed-loop automated insulin delivery system. Key competitor is Medtronic (MDT), Tandem Diabetes Care (TNDM) and others. Market share data is provided in the 'Competitors' section.
Market Dynamics
Industry Overview
The diabetes management industry is experiencing growth driven by the increasing prevalence of diabetes and advancements in insulin delivery technology. The market is competitive, with companies focusing on innovation and patient-centric solutions.
Positioning
Insulet is positioned as an innovator in the insulin delivery market with its tubeless pump technology. Its competitive advantage lies in the convenience and ease of use of its Omnipod system.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach hundreds of billions of dollars. Insulet is positioned well to capture a significant share of this market through its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative tubeless pump technology
- Strong brand recognition
- Growing user base
- Automated insulin delivery advancements with Omnipod 5
- Disposable product leads to recurring revenue
Weaknesses
- Reliance on a single product platform (Omnipod)
- Higher cost compared to traditional insulin delivery methods
- Competition from established players with broader product portfolios
Opportunities
- Expanding into new geographic markets
- Developing partnerships with healthcare providers
- Integrating with continuous glucose monitoring (CGM) systems
- Further automation and AI in insulin delivery
Threats
- Increasing competition from other pump manufacturers
- Regulatory changes affecting medical devices
- Reimbursement pressures from insurance companies
- Technological disruption from new diabetes management solutions
Competitors and Market Share
Key Competitors
- MDT
- TNDM
- BMRA
Competitive Landscape
Insulet differentiates itself with its tubeless pump design, while competitors offer traditional pumps with varying features. Insulet's innovative product offering and focus on user experience provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Insulet has experienced significant revenue growth driven by increasing adoption of the Omnipod system.
Future Projections: Analysts project continued revenue growth for Insulet, fueled by international expansion and new product introductions.
Recent Initiatives: Recent initiatives include the launch of the Omnipod 5, expansions in manufacturing capacity, and strategic partnerships with technology companies.
Summary
Insulet is a strong company with a leading position in the tubeless insulin pump market. The Omnipod system's innovative design and user-friendly interface drive revenue growth. The company must address competition and reimbursement challenges to maintain its growth trajectory. Expanding internationally and developing new products will be important for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Insulet Corporation
Exchange NASDAQ | Headquaters Acton, MA, United States | ||
IPO Launch date 2007-05-15 | CEO, President & Director Ms. Ashley A. McEvoy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.insulet.com |
Full time employees 3900 | Website https://www.insulet.com | ||
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.